The Short Answer: Both medications produce real, lasting weight loss. Tirzepatide produced more weight loss in the only head-to-head trial, but semaglutide has a longer safety track record, more formats (including a daily pill), and proven heart benefits in people without diabetes. The "better" one depends on your health, your goals, and how your body handles side effects.
If you've heard the names Ozempic, Wegovy, Mounjaro or Zepbound, you've heard of these two drugs. Here's what they are, how they work, and how to think about which one fits you.
What is Semaglutide?
Semaglutide is a GLP-1 receptor agonist made by Novo Nordisk. It copies a natural gut hormone your body releases after eating. It's sold under different brand names depending on the use:
Ozempic — weekly injection for type 2 diabetes.
Wegovy — weekly injection for chronic weight management, up to 2.4 mg.
Wegovy HD — a higher 7.2 mg weekly dose, approved by the FDA in March 2026. It's for people who have tolerated 2.4 mg for at least four weeks and need more weight loss.
Wegovy pill — a once-daily 25 mg tablet, approved in December 2025 as the first oral GLP-1 for weight loss.
Semaglutide has been studied for years in large trials. Wegovy is also approved to lower the risk of heart attack, stroke and cardiovascular death in adults with heart disease and excess weight.
What is Tirzepatide?
Tirzepatide is made by Eli Lilly. It's a single molecule that acts on two hormone receptors instead of one: GLP-1 and GIP. It's the first "dual agonist" approved for weight loss.
Mounjaro — weekly injection for type 2 diabetes.
Zepbound — weekly injection for chronic weight management, from 2.5 mg up to 15 mg. Zepbound is also approved to treat moderate-to-severe obstructive sleep apnea in adults with obesity.
Tirzepatide is newer than semaglutide, so its long-term data is shorter. In a large trial of people with type 2 diabetes and heart disease, it protected the heart at least as well as an older GLP-1 drug, with 16% fewer deaths from any cause. A heart-outcomes trial in people with obesity but no diabetes is still running.
How they work for weight loss
Both drugs mimic "incretin" hormones your gut releases after a meal. Those hormones tell your brain and body you've eaten. The result is less hunger and fewer calories, without relying on willpower alone.
What both drugs do:
Turn down appetite in the brain. They act on brain areas that regulate hunger and food cravings. Many patients describe quieter "food noise."
Slow stomach emptying. Food stays in the stomach longer, so you feel full sooner and stay full longer.
Steady blood sugar. They help the pancreas release insulin when blood sugar rises, which reduces spikes and crashes.
Where tirzepatide differs: it also activates the GIP receptor. GIP and GLP-1 receptors overlap in some tissues and not in others, and researchers think this dual action may explain tirzepatide's larger weight loss.
Head to head: what the research shows
In the SURMOUNT-5 trial, people on tirzepatide lost an average of 20.2% of their body weight over 72 weeks, versus 13.7% on semaglutide. The trial enrolled 751 adults with obesity but without type 2 diabetes, each on the highest dose they could tolerate. Results were published in the New England Journal of Medicine in May 2025.
A few things to keep in mind:
Both worked. A 13.7% loss is still large and medically meaningful.
The trial was open-label and sponsored by Eli Lilly. Still, the results closely match earlier blinded trials of each drug.
Newer semaglutide doses weren't tested. Wegovy HD (7.2 mg) produced about 18.7% to 20.7% average loss in its own trials. It has not been compared directly with tirzepatide.
The Wegovy pill produced 16.6% average loss over 64 weeks in people who stayed on treatment.
Side effects and safety
The two drugs share a similar side-effect profile, and most effects are digestive and mild to moderate. In SURMOUNT-5, overall side effects were similar between the two, though tirzepatide caused more injection-site reactions.
Common side effects (usually worst while the dose is increasing):
Nausea, vomiting, diarrhea or constipation
Reduced appetite, bloating, heartburn
Fatigue
Less common but serious risks include pancreatitis, gallbladder problems, kidney strain from dehydration, and low blood sugar when combined with some diabetes medicines. Higher doses bring more side effects: on Wegovy HD, about 23% of people reported unusual skin sensations like tingling or burning.
Who should not take either drug: People with a personal or family history of medullary thyroid cancer or MEN 2 syndrome, and people who are pregnant or planning pregnancy.
A note on compounded versions. Compounded semaglutide and tirzepatide are not FDA-approved, and the FDA has stepped up enforcement in 2026. By May 2026 it had logged more than 1,700 adverse-event reports tied to compounded versions. Ask your provider exactly what you're getting and where it comes from.
Which one is better for you?
There's no single winner for everyone. Tirzepatide wins on average weight loss, while semaglutide wins on track record, format options and proven heart protection in people without diabetes.
If you want the most weight loss possible: Tirzepatide is often the better fit. It produced the largest average loss in the head-to-head trial.
If you have heart disease and excess weight, but not diabetes: Semaglutide is often the better fit. Wegovy is approved to reduce heart attack and stroke risk in this group.
If you'd rather take a pill than a shot: Semaglutide is often the better fit. The Wegovy pill is a daily tablet option.
If you have obstructive sleep apnea: Tirzepatide is often the better fit. Zepbound is approved to treat sleep apnea in adults with obesity.
If you have type 2 diabetes: Either can work. Both lower A1C and weight, and your provider will weigh your other medicines.
If you stopped one drug because of side effects: Try the other. Some people tolerate one better than the other.
If your insurance covers only one: Choose the covered one. Both work well, and the best drug is one you can stay on.
Other factors your provider will look at:
Your health history, current medicines and lab work
How much weight you need to lose to reach your health goals
Cost, insurance coverage and self-pay options
Plans for pregnancy
Whichever you choose, results are best when the medication is paired with enough protein, strength training and regular check-ins. That helps protect muscle while you lose fat. Most people regain weight if they stop treatment, so plan for the long term.
Frequently asked questions
Are Ozempic and Wegovy the same drug? Yes, both are semaglutide. Ozempic is approved for type 2 diabetes, and Wegovy is approved for weight management at different doses.
Are Mounjaro and Zepbound the same drug? Yes, both are tirzepatide. Mounjaro is for type 2 diabetes, and Zepbound is for weight management and sleep apnea.
Can I switch from semaglutide to tirzepatide? Often, yes. Your provider will choose a starting dose based on what you were taking and how you tolerated it.
Is there a tirzepatide pill? No. Eli Lilly's weight-loss pill, Foundayo (orforglipron), is a different GLP-1 drug, approved in April 2026.
How fast will I see results? Many people notice less hunger within the first few weeks. Weight loss builds gradually as the dose increases, with the largest results seen over about a year to 18 months.
Please consult with a licensed provider before starting. Like us!
Sources
Tirzepatide demonstrates greater weight loss than semaglutide (Patient Care)
FDA approves higher-dose Wegovy (University of Minnesota College of Pharmacy)
This article is for general education only and is not medical advice. Talk with a licensed provider before starting, stopping or changing any medication.
